LONDON -- The FTSE 100 (FTSEINDICES: ^FTSE ) has continued its recent nosedive today, plunging a further 127 points to 6,033 by 8:30 a.m. EDT. Worries about the Chinese economy have been blamed for the slump, with fears of a liquidity squeeze coming to the fore. And last week's news that the U.S. Federal Reserve is likely to scale back its economic-stimulus measures is still weighing heavily.
Unsurprisingly, there are few individual shares doing well today, but it doesn't take much to beat a falling FTSE. Here are three that look likely to achieve that today.
Vodafone
Vodafone Group shares are flat this morning, avoiding the precipitous drop of the broader market. The reason? The telecom giant has confirmed that it has all but sealed its planned acquisition of Kabel Deutschland Holding through a voluntary public tender offer.
Vodafone is offering ��4.50 per share, plus the ��.50 dividend already announced by the firm, making a total of ��7 -- and valuing Kabel Deutschland at ��.7 billion (approximately 拢6.6 billion). The management and supervisory boards of Kabel Deutschland intend to recommend the offer to shareholders.
Top 5 Low Price Companies To Watch In Right Now: Celgene Corp (CELG)
Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.
The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.
Commercial! Stage Products
REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.
REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.
THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.
ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.
Preclinical and Clinical-Stage Pipeline
The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.
The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).
The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.
At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.
The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.
The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).
Advisors' Opinion:- [By Keith Speights]
Compared to other biotechs, Amgen's valuation based on trailing P/E looks attractive. Regeneron sports a trailing P/E ratio of 35, while Gilead's multiple stands at 31. Biogen Idec (NASDAQ: BIIB ) and Celgene (NASDAQ: CELG ) are even pricier, with trailing P/E values near 37.
- [By Ben Levisohn]
J&J’s Velcade sales could be a good sign for Celgene (CELG) shareholders, according to Yee and team:
Velcade ex-US sales were $404M, up +7% Q/Q, likely due to continued growth with new SubQ formulation (much lower neuropathy tox) and EU approval as induction therapy in combination w/ dex or thalomid-dex in “first line” transplant eligible MM patients (EU approved August 2013). We think CELG puts up a solid Q3 too driven by market growth and increasing duration of therapy.
- [By Ben Levisohn]
Look at Celgene (CELG) and Alexion Pharmaceuticals (ALXN) –Big Cap Biotech stocks that smashed through consensus EPS estimates in Q3 and upped guidance too. One of our biggest overweights in the U.S. portfolios is the Health Care sector.
- [By Ben Levisohn]
Remember when biotech stocks like Gilead Sciences (GILD) and Celgene (CELG) were getting creamed and everyone was wondering if the biotech boom was finished? Yeah, neither do I.
Top 5 Net Payout Yield Stocks To Buy Right Now: Sinovac Biotech Ltd.(SVA)
Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against the hepatitis A, hepatitis B, and influenza viruses in the People's Republic of China. It offers Healive, an inactivated hepatitis A vaccine; Bilive, a combination of hepatitis A and B vaccine; Anflu, a split virus influenza vaccine; and Panflu, a vaccine against the influenza A H1N1 virus. The company's pipeline vaccine candidates include a split viron vaccine, which completed Phase II clinical trials for the H5N1 influenza virus; and a SARS vaccine, which completed Phase I clinical trials for the SARS virus. In addition, its pipeline vaccine candidates that completed the pre-clinical trials comprise human vaccines for EV71, pneumococcal conjugate, haemophilus influenzae type b, meningitis, Japanese encephalitis, chickenpox, mumps, and rubella diseases, as well as rabies vaccine for humans and animals. The company markets and sell s its vaccine products directly to the provincial and municipal disease control and prevention centers. It has a patent license agreement with the National Institutes of Health; distribution agreements with LG Life Sciences, Ltd. and Glovax C.V.; and a pandemic influenza vaccine co-development agreement with the China Center for Disease Control and Prevention. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.
Advisors' Opinion:- [By Rich Duprey]
Troubling is that it's a new presence in humans, and while that makes its spread among the populace difficult, scientists fear that it's gaining momentum. Sinovac Biotech (NASDAQ: SVA ) , which was approved to produce vaccines several years ago, jumped almost 7% yesterday as it gears up to mass produce a vaccine to combat the new threat.
Top 5 Net Payout Yield Stocks To Buy Right Now: CBL & Associates Properties Inc. (CBL)
CBL & Associates Properties, Inc. is a public real estate investment trust. It engages in acquisition, development, and management of properties. The fund invests in the real estate markets of United States. Its portfolio consists of enclosed malls and open-air centers. CBL & Associates Properties is based in Oak Brook, Illinois. CBL & Associates Properties was founded in 1978 and is based in Chattanooga, Tennessee.
Advisors' Opinion:- [By Marc Bastow]
Regional shopping mall real estate investment trust (REIT) CBL & Associates (CBL) raised its quarterly dividend 6.5% to 24.5 cents per share, payable on Jan. 15 to shareholders of record as of Dec. 30.
CBL Dividend Yield: 5.44% - [By Monica Gerson]
CBL & Associates Properties (NYSE: CBL) shares fell 5.20% to reach a new 52-week low of $18.43 after the company reported Q3 results.
VIVUS (NASDAQ: VVUS) shares dipped 11.58% to touch a new 52-week low of $8.32 on weak sales of Qsymia. Bank of America downgraded VIVUS from Buy to Neutral.
Top 5 Net Payout Yield Stocks To Buy Right Now: Viasystems Group Inc.(VIAS)
Viasystems Group, Inc. provides multi-layer printed circuit boards (PCBs) and electro-mechanical solutions worldwide. The company?s products and services are used in a range of applications, including, automotive engine controls, data networking equipment, telecommunications switching equipment, complex medical, technical and industrial instruments, and flight control systems. Its PCBs products include circuitry and mounting surfaces to interconnect discrete electronic components, such as integrated circuits, capacitors, and resistors. The company?s electro-mechanical solutions comprise assembly of backplanes, assembly of printed circuit boards, fabrication of custom and standard metal enclosures, cabinets, racks, sub-racks and bus bars; systems integration; final assembly; and product testing and fulfillment. It also offers various manufacturing services consisting of design and prototyping, PCB and backpanel fabrication, backpanel assembly, PCB assembly, custom metal e nclosure fabrication, full system assembly and test, packaging and global distribution, after-sales support, and supply chain management. The company markets its products and services to original equipment manufacturers and contract electronic manufacturers in automotive, industrial and instrumentation, telecommunications, computer and data communications, and military and aerospace markets through its own sales and marketing organization, and through relationships with independent sales agents. The company was formerly known as Circo Technologies, Inc. and changed its name to Viasystems Group, Inc. in January 1997. Viasystems Group, Inc. was founded in 1996 and is headquartered in St. Louis, Missouri.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Viasystems Group (Nasdaq: VIAS ) , whose recent revenue and earnings are plotted below. - [By Luke Jacobi]
Shares of Viasystems Group (NASDAQ: VIAS) got a boost, shooting up 35 percent to $15.80 after TTM Technologies (NASDAQ: TTMI) announced its plans to buy Viasystems for a total value of $16.46 per share.
- [By Garrett Cook]
Shares of Viasystems Group (NASDAQ: VIAS) got a boost, shooting up 35.81 percent to $15.89 after TTM Technologies (NASDAQ: TTMI) announced its plans to buy Viasystems for a total value of $16.46 per share.
No comments:
Post a Comment